Skip to main content

Research Repository

Advanced Search

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

People Involved

Professor Andrew Clark

Project Description

Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study drug which facilitates heart muscle contraction via interaction with the actin - myosin complex, versus placebo.

Project Acronym Galactic-HF
Status Project Complete
Value £110,723.00
Project Dates Apr 1, 2017 - Jul 31, 2021
Partner Organisations Hull University Teaching Hospitals NHS Trust

You might also like

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - w... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.